<html><head></head><body><h1>Peditrace</h1><p class="drug-subtitle"><b>Generic Name:</b> zinc, copper, manganese, selenium, fluorine, and iodine<br/>
<b>Dosage Form:</b> injection, solution<br/></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li><b class="nav-item here">Professional</b></li>
<li>Interactions</li>
<li class="nav-more">
More&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewBox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/body&gt;&lt;/html&gt;
</li>
</ul><ul>
<li>Medication Guide</li>
</ul><p class="First"><span class="Bold"><span class="Emphasis">1      QUALITATIVE AND QUANTITATIVE COMPOSITION<br/></span></span></p><p>1 ml of Peditrace contains:</p><p><span class="Bold"><span class="Emphasis">Active ingredients</span></span> <span class="Bold"><span class="Emphasis">Quantity</span></span></p><p>Zinc chloride                              521 µg</p><p>Copper chloride  2H<span class="Sub">2</span>O              53.7 µg</p><p>Manganese chloride 4H<span class="Sub">2</span>O         3.60 µg</p><p>Sodium selenite anhydrous        4.38 µg</p><p>Sodium fluoride                          126 µg</p><p>Potassium iodide                        1.31 µg</p><p>The active ingredients in 1 ml of Peditrace correspond to</p><p>Zn           250 µg           3.82  µmol</p><p>Cu           20 µg             0.315 µmol</p><p>Mn          1 µg               18.2  nmol</p><p>Se            2 µg               25.3  nmol</p><p>F              57 µg             3.00  µmol</p><p>I               1 µg               7.88  nmol</p><p>The contents of sodium and potassium correspond to</p><p>Sodium           70 µg           3.05 µmol</p><p>Potassium       0.31 µg        7.88 nmol</p><p>For excipients, see 5.1.</p><p>PRODUCT PROPERTIES</p><p>•    Osmolality 38 mosm/kg water</p><p>•    pH: 2.0</p><p><span class="Bold"><span class="Emphasis">2      PHARMACEUTICAL FORM<br/></span></span></p><p>Concentrate for solution for infusion</p><p><span class="Bold"><span class="Emphasis">3      CLINICAL PARTICULARS<br/></span></span></p><p><span class="Bold"><span class="Emphasis">3.1   Therapeutic indications</span></span></p><p>Peditrace is indicated in premature and full-term infants and children needing intravenous nutrition to supply the basal requirements of trace elements.</p><p><span class="Bold"><span class="Emphasis">3.2   Posology and method of administration</span></span></p><p>Peditrace must not be given undiluted.</p><p>The recommended dose is 1 ml Peditrace/kg body weight/day for infants and children with a weight of up to 15 kg. The basic requirements of trace elements are covered by a daily dose of 15 ml to children weighing more than 15 kg.</p><p><span class="Bold"><span class="Emphasis">3.3   Contraindications</span></span></p><p>Wilson’s Disease.</p><p><span class="Bold"><span class="Emphasis">3.4   Special warnings and special precautions for use</span></span></p><p>Peditrace should be used with caution in patients with impaired biliary and/or renal function, in whom the excretion of trace elements may be significantly decreased.</p><p>Peditrace should also be used with caution in patients with biochemical or clinical evidence of liver dysfunction (especially cholestasis).</p><p>If the treatment is continued for more than 4 weeks, checking of manganese levels is required.</p><p>Patients with increased losses or requiring prolonged intravenous nutrition should be monitored biochemically to confirm the requirements are being met appropriately.</p><p><span class="Bold"><span class="Emphasis">3.5   Interaction with other medicinal products and other forms of interac</span></span>tion</p><p>No interactions with other drugs have been observed.</p><p><span class="Bold"><span class="Emphasis">3.6   Pregnancy and lactation</span></span></p><p>Not applicable.</p><p><span class="Bold"><span class="Emphasis">3.7   Effects on ability to drive and use machines</span></span></p><p>Not applicable.</p><p><span class="Bold"><span class="Emphasis">3.8   Undesirable effects</span></span></p><p>No adverse effects related to the trace elements in Peditrace have been reported.</p><p>Superficial thrombophlebitis has been observed when glucose containing Peditrace was given. However, it is not possible to deduce whether this reaction is attributable to the trace elements infusion or not.</p><p>Allergic reactions to iodine may occur following topical application. No adverse reactions are known to occur as a consequence of using the recommended intravenous iodide dosage levels.</p><p><span class="Bold"><span class="Emphasis">3.9   Overdose</span></span></p><p>In patients with impaired renal or biliary function, there is an increased risk for accumulation of trace elements.</p><p><span class="Bold"><span class="Emphasis">4      PHARMACOLOGICAL PROPERTIES<br/></span></span></p><p><span class="Bold"><span class="Emphasis">4.1   Pharmacodynamic properties</span></span></p><p>Peditrace is a mixture of trace elements in amounts normally absorbed from the oral diet and should have no pharmacodynamic effect besides maintaining or repleting nutritional status.</p><p><span class="Bold"><span class="Emphasis">4.2   Pharmacokinetic properties</span></span></p><p>When infused intravenously the trace elements in Peditrace are handled in a similar way to trace elements from an oral diet. Individual trace elements will be taken up by tissues to different extents, depending on the requirement within each tissue to maintain or restore the concentration of each element for the metabolic requirement of that tissue.</p><p>Copper and manganese are normally excreted via the bile, whereas selenium and zinc (especially in patients receiving intravenous nutrition) are mainly excreted via the urine.</p><p><span class="Bold"><span class="Emphasis">4.3   Preclinical safety data</span></span></p><p>The safety evaluation is based mainly on clinical experience and documentation.</p><p><span class="Bold"><span class="Emphasis">5      PHARMACEUTICAL PARTICULARS</span></span></p><p><span class="Bold"><span class="Emphasis">5.1   List of excipients</span></span></p><p>Hydrochloric acid           </p><p>Water for injections</p><p><span class="Bold"><span class="Emphasis">5.2   Incompatibilities</span></span></p><p>Peditrace may only be added to or mixed with other medicinal products for which compatibility has been documented. See 5.6.</p><p><span class="Bold"><span class="Emphasis">5.3   Shelf‑life</span></span></p><p>3 years.</p><p><span class="Bold"><span class="Emphasis">5.4   Special precautions for storage</span></span></p><p>Do not store above 25°C. Do not freeze.</p><p><span class="Bold"><span class="Emphasis">5.5   Nature and content of container</span></span></p><p>Vial for injection, polypropylene plastic.</p><p>Pack size: 10 x 10 ml</p><p><span class="Bold"><span class="Emphasis">5.6   Instructions for use and handling</span></span></p><p>COMPATIBILITY</p><p>Additions should be made aseptically.</p><p><span class="Bold"><span class="Emphasis">Additions</span></span></p><p>Up to 6 ml Peditrace can be added to 100 ml Vaminolact, Vamin 9 Electrolyte Free, Vamin 14 Electrolyte Free or glucose solution (50-500 mg/ml).</p><p>INFUSION TIME</p><p>The infusion time should not be less than 8 hours. The infusion should be given at a very slow rate.</p><p>STABILITY</p><p>When additions are made to an infusion solution, the infusion should be completed within 24 hours from preparation to prevent microbiological contamination. The left-over contents of opened bottles/vials/ampoules should be discarded and not kept for later use.</p><p class="First"><span class="Bold"><span class="Emphasis">Peditrace™</span></span></p><p><span class="Bold"><span class="Emphasis">10 ml</span></span></p><p>Concentrate for solution for infusion</p><p> </p><p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Peditrace 10 mL Vial Carton Panel</span></span></p><p>10 vials of 10 ml</p><p><span class="Bold"><span class="Emphasis">Peditrace™</span></span></p><p>Concentrate for solution for infusion</p><p> </p><h2>More about Peditrace (trace elements)</h2><ul class="more-resources-list more-resources-list-general">
<li>Drug Interactions</li>
<li>Drug class: intravenous nutritional products</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Total Parenteral Nutrition</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>